Mylan Inc

MYL-Q

NASDAQ:MYL

19.02
0.27 (1.40%)
Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and global headquarters in Canonsburg, Pennsylvania, US.
More at Wikipedia

Analysis and Opinions about MYL-Q

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
August 10, 2017

TEVA-N vs. MYL-Q. He does not like either at these prices. They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals. The FDA is going to alleviate the delays on getting new drugs to market. He wants to be in pharmas that have innovation. He is concerned about how their business model will fair over the next 5 years.

Mylan Inc (MYL-Q)
August 10, 2017

TEVA-N vs. MYL-Q. He does not like either at these prices. They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals. The FDA is going to alleviate the delays on getting new drugs to market. He wants to be in pharmas that have innovation. He is concerned about how their business model will fair over the next 5 years.

Robert Lauzon
Deputy Chief Investment Officer, Middlefield Capital Corporation
Price
$32.290
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
February 22, 2017

(A Top Pick Feb 8/16. Down 16.58%.) Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). Unfortunately both stocks came down.

Mylan Inc (MYL-Q)
February 22, 2017

(A Top Pick Feb 8/16. Down 16.58%.) Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). Unfortunately both stocks came down.

Jerome Hass
Portfolio Manager, Lightwater Partners
Price
$42.000
Owned
Yes
HOLD
HOLD
January 30, 2017

Epi Pens. They are very expensive, $600 each. They then offered a $300 generic version. There are now competitors, but they own 90% of the market place. The stock took a bit of a hit, but she still likes it and thinks they will keep market share even if prices come down a bit for Epi Pens.

Mylan Inc (MYL-Q)
January 30, 2017

Epi Pens. They are very expensive, $600 each. They then offered a $300 generic version. There are now competitors, but they own 90% of the market place. The stock took a bit of a hit, but she still likes it and thinks they will keep market share even if prices come down a bit for Epi Pens.

Erin Gibbs
V.P., S&P Global Market Intelligence
Price
$36.340
Owned
Unknown
DON'T BUY
DON'T BUY
January 30, 2017

People really hate this, and unfortunately it has become one of the poster children of aggressive drug pricing, high compensation of the C suite, the EpiPen debacle, and kind of a lacklustre performance. Thinks this is going to be under a lot of pressure. He would suggest that you switch into Celgene (CELG-Q).

Mylan Inc (MYL-Q)
January 30, 2017

People really hate this, and unfortunately it has become one of the poster children of aggressive drug pricing, high compensation of the C suite, the EpiPen debacle, and kind of a lacklustre performance. Thinks this is going to be under a lot of pressure. He would suggest that you switch into Celgene (CELG-Q).

John Stephenson
President & CEO, Stephenson & Company Capital Management
Price
$36.340
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
December 29, 2016

(A Top Pick Feb 8/16. Down 25.9%.) Long. (A Pairs trade with Valeant Pharmaceuticals (VRX-T).)

Mylan Inc (MYL-Q)
December 29, 2016

(A Top Pick Feb 8/16. Down 25.9%.) Long. (A Pairs trade with Valeant Pharmaceuticals (VRX-T).)

Jerome Hass
Portfolio Manager, Lightwater Partners
Price
$37.380
Owned
Yes
BUY
BUY
December 23, 2016

They jacked up the price of the EpiPen and it gave a whole credibility issue problem to the company and brought it under some pressure. Healthcare and technology are those things that are going to grow in almost any market environment over the next number of years. This company is pretty well positioned. They argued their case effectively.

Mylan Inc (MYL-Q)
December 23, 2016

They jacked up the price of the EpiPen and it gave a whole credibility issue problem to the company and brought it under some pressure. Healthcare and technology are those things that are going to grow in almost any market environment over the next number of years. This company is pretty well positioned. They argued their case effectively.

John Zechner
Chairman, J. Zechner & Assoc
Price
$37.500
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
October 4, 2016

(An update from Jerome!) (A Top Pick Feb 8/16.) Long. He covered this on Aug 25/16. This is not a name he would probably go back to.

Mylan Inc (MYL-Q)
October 4, 2016

(An update from Jerome!) (A Top Pick Feb 8/16.) Long. He covered this on Aug 25/16. This is not a name he would probably go back to.

Jerome Hass
Portfolio Manager, Lightwater Partners
Price
$37.970
Owned
No
TOP PICK
TOP PICK
February 8, 2016

Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). In a Pair trade you really have conviction on both sides. In this instance, while he likes Mylan as a Long hedge position, the conviction actually lies with Valeant as a Short, which still has a lot of fundamental problems ahead of them.

Mylan Inc (MYL-Q)
February 8, 2016

Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). In a Pair trade you really have conviction on both sides. In this instance, while he likes Mylan as a Long hedge position, the conviction actually lies with Valeant as a Short, which still has a lot of fundamental problems ahead of them.

Jerome Hass
Portfolio Manager, Lightwater Partners
Price
$50.450
Owned
Yes
BUY
BUY
October 7, 2004
Recently acquired King Pharmaceuticals.
Mylan Inc (MYL-Q)
October 7, 2004
Recently acquired King Pharmaceuticals.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$17.390
Owned
Yes
Showing 1 to 9 of 9 entries
  • «
  • 1
  • »